

ClinicalTrials.gov Search Results 01/17/2024

	Title	Status	Study Results	Conditions	Interventions	Locations
1	<a href="#">Factors Influencing the COVID-19 Vaccine Immune Response According to Age and Presence or Not of a Past History of COVID-19</a>	Completed	No Results Available	•Covid19	•Biological: COVID-19 vaccine Pfizer (2 doses)  •Biological: COVID-19 vaccine Pfizer (1 dose)  •Biological: COVID-19 mRNA Vaccine Moderna (2 doses)  •Biological: COVID-19 mRNA Vaccine Moderna (1 dose)	•HCL - Hôpital Croix Rousse, Lyon, France  •CHU de Saint-Etienne, Saint-Étienne, France
2	<a href="#">The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection</a>	Recruiting	No Results Available	•COVID-19  •Vaccine-Preventable Diseases  •SARS CoV 2 Infection  •Upper Respiratory Tract Infection  •Upper Respiratory Disease	•Biological: Novavax COVID-19 vaccine (2023-2024 formula XBB containing)  •Biological: Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing)	•University of Utah School of Medicine, Salt Lake City, Utah, United States
3	<a href="#">Effectiveness and Use of COVID-19 Vaccines Using Information From the California State Vaccine Registry</a>	Recruiting	No Results Available	•SARS-CoV-2  •COVID-19  •Post-Acute COVID-19 Syndrome	•Biological: Pfizer-BioNTech COVID-19 bivalent mRNA vaccine	•Pfizer, New York, New York, United States
4	<a href="#">Pfizer-BioNTech COVID-19 BNT162b2 Vaccine Effectiveness Study - Kaiser Permanente Southern California</a>	Recruiting	No Results Available	•COVID-19	•Biological: Primary Exposure Status of Pfizer-BioNTech COVID-19 Vaccine  •Biological: Bivalent vaccinated	•Kaiser Permanente Southern California, Pasadena, California, United States
5	<a href="#">The BOOSTED (Booster Options Or Switching Tested for Effectiveness and Downsides Study) Trial (COVID-19)</a>	Completed	No Results Available	•COVID-19  •Vaccine Reaction  •COVID-19 Pandemic	•Behavioral: Moderna Booster Vaccine  •Behavioral: Pfizer Booster Vaccine	•UCSF Parnassus, San Francisco, California, United States
6	<a href="#">Randomized, Single-blinded, Multicenter Trial Comparing the Immune Response to a 2nd Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNTech) or Sanofi /GSK B.1.351 Adjuvanted Vaccine in Adults</a>	Active, not recruiting	No Results Available	•COVID-19 Vaccines	•Biological: 2nd booster with Comirnaty® (Pfizer-BioNTech)  •Biological: CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK	•GH Broca-Cochin-Hôtel-Dieu CIC 1417 Cochin-Pasteur, Paris, France
7	<a href="#">Immunogenicity and Reactogenicity of the Beta-variant Recombinant Protein Booster Vaccine (VidPrevtn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine</a>	Active, not recruiting	No Results Available	•Vaccine Reaction  •COVID-19	•Biological: Comirnaty® BNT162b2 / Omicron BA.4-5 vaccine (Pfizer-BioNTech)  •Biological: VidPrevtn® Beta vaccine (Sanofi/GSK)	•CIC 1417 Cochin-Pasteur, Paris, France
8	<a href="#">Immunogenicity and Reactogenicity Following a Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNtech) and Two Adjuvanted Sub-unit Vaccines (SP/GSK) Administered in Adults Who Received 2 Doses of Pfizer-BioNTech mRNA Vaccine as a Primary Vaccination</a>	Active, not recruiting	No Results Available	•COVID-19  •Vaccine Reaction	•Biological: BNT162b2  •Biological: CoV2 preS dTM adjuvanted vaccine (D614), Sanofi/GSK  •Biological: CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK	•GH Broca-Cochin-Hôtel-Dieu CIC 1417 Cochin-Pasteur, Paris, France

	Title	Status	Study Results	Conditions	Interventions	Locations
9	<a href="#">PTX-COVID19-B, an mRNA Humoral Vaccine, Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Demonstrate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B in Comparison to the Pfizer-BioNTech COVID-19 Vaccine.</a>	Completed	No Results Available	•Covid19 Vaccine	•Biological: PTX-COVID19-B  •Biological: Pfizer-BioNTech COVID-19 vaccine  •Biological: Placebo	•LMC Clinical Research Inc. (Calgary), Calgary, Alberta, Canada  •Malton Medical, Mississauga, Ontario, Canada  •Red Maple, Ottawa, Ontario, Canada  •Pharma Medica Research Inc., Toronto, Ontario, Canada  •Manna Bayview, Toronto, Ontario, Canada  •Manna Toronto, Toronto, Ontario, Canada  •Wits Vaccines & Infections Diseases Analytics (VIDA) Research Unit, Johannesburg, Gauten, South Africa  •MERC Middleburg, Middleburg, Mpumalanga, South Africa  •TREAD Research, Cape Town, Western Cape, South Africa  •UCT Lung Institute, Cape Town, Western Cape, South Africa  •Be Part Research, Paarl, Western Cape, South Africa
10	<a href="#">Impact of the Immune System on Response to Anti-Coronavirus Disease 19 (COVID-19) Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo)</a>	Recruiting	No Results Available	•Coronavirus Disease 2019 (Covid19)  •Hematopoietic Neoplasms	•Drug: anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)	•CHU Liège, Domaine du Sart-Tilman, Liège, Belgium
11	<a href="#">Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction</a>	Recruiting	No Results Available	•COVID-19  •Corona Virus Infection	•Biological: Pfizer-BioNTech mRNA COVID-19 vaccine  •Biological: Moderna mRNA COVID-19 vaccine	•University of Michigan, Ann Arbor, Michigan, United States
12	<a href="#">Third Dose Vaccination With AstraZeneca or Pfizer COVID-19 Vaccine Among Adults Received Sinovac COVID-19 Vaccine</a>	Completed	No Results Available	•COVID-19 Infection  •COVID-19 VACCINE	•Biological: AstraZeneca ChAdOx1 AZD1222 vaccine (AZ) full dose  •Biological: Pfizer/BioNTech BNT162b2 vaccine (PF) full dose  •Biological: AstraZeneca ChAdOx1 AZD1222 vaccine (AZ) half dose  •Biological: Pfizer/BioNTech BNT162b2 vaccine (PF) half dose	•Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok Noi, Bangkok, Thailand  •Faculty of Medicine Chulalongkorn University, Pathum Wan, Bangkok, Thailand  •Faculty of Medicine Thammasat University, Khlong Luang, Pathum Thani, Thailand  •Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi hospital, Mahidol University, Bang Phli, Samut Prakan, Thailand  •Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkla, Thailand  •Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand  •Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
13	<a href="#">This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times.</a>	Completed	No Results Available	•Influenza, Human  •COVID-19	•Biological: Comirnaty  •Biological: Quadrivalent Influenza Vaccine	•Pfizer, New York, New York, United States
14	<a href="#">mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs</a>	Active, not recruiting	No Results Available	•Immunogenicity  •Safety  •Efficacy	•Biological: SW-BIC-213;SARS-Cov-2.  •Biological: Sinopharm (BIBP);SARS-Cov-2.  •Biological: Pfizer(BNT162b2);SARS-Cov-2.	•Savannakhét Provincial hospital, Savannakhét, Sava, Lao People's Democratic Republic
15	<a href="#">The Impact of COVID-19 on Maternal and Neonatal Outcomes</a>	Recruiting	No Results Available	•COVID-19  •Pregnancy; Infection	•Biological: mRNA COVID-19 vaccine (Pfizer or Moderna)	•Johns Hopkins Hospital, Baltimore, Maryland, United States
16	<a href="#">COVID-19 Protection After Transplant Pilot Study</a>	Completed	No Results Available	•Kidney Transplant Recipients	•Biological: mRNA-1273 vaccine (Pfizer/ BioNTech)  •Biological: mRNA-1273 vaccine (Moderna)	•Johns Hopkins Hospital, Baltimore, Maryland, United States
17	<a href="#">Role of Vit-D Supplementation on BioNTech, Pfizer Vaccine Side Effect and Immunoglobulin G Response</a>	Completed	No Results Available	•COVID-19 Respiratory Infection	•Combination Product: Vitamin-D	•Hawal Lateef Fateh, Sulaymaniyah, Iraq

	Title	Status	Study Results	Conditions	Interventions	Locations
18	<a href="#">Fourth Dose of mRNA COVID-19 Vaccine in Residents of LTCFs</a>	Not yet recruiting	No Results Available	•SARS-CoV2 Infection •Coronavirus Infection	•Drug: mRNA- COVID-19 •Drug: Prevnar13	•McMaster University, Hamilton, Ontario, Canada
19	<a href="#">COVID-19 Vaccine Boosters in Patients With CKD</a>	Terminated	No Results Available	•Chronic Kidney Diseases •COVID-19	•Biological: Pfizer-BioNTech COVID-19 Vaccine •Biological: MODERNA SARS-CoV-2 Vaccine	•Scarborough Health Network, Scarborough, Ontario, Canada •University Health Network, Toronto, Ontario, Canada •Sunnybrook Health Science Center, Toronto, Ontario, Canada
20	<a href="#">Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia.</a>	Active, not recruiting	No Results Available	•COVID-19	•Biological: Tozinameran - Standard Dose •Biological: Tozinameran - Fractional Dose	•District Health Centre, Ulaanbaatar, Mongolia
21	<a href="#">A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine in Brazil</a>	Completed	No Results Available	•Covid19	•Drug: Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine •Drug: CoronaVac COVID-19 vaccine •Drug: ChAdOx1 nCoV-19 Covid-19 Vaccine •Drug: Ad26.COV2.S COVID-19 Vaccine	•Pronto Atendimento Municipal de Toledo, Toledo, Paraná, Brazil •Unidade Básica de Saúde Jardim Cosmos, Toledo, PR, Brazil •Unidade de Pronto Atendimento Pediátrico Dr. José Ivo Alves da Rocha, Toledo, PR, Brazil
22	<a href="#">Cardiac Manifestation in Adolescent After Pfizer COVID-19 Injection in Thailand</a>	Completed	No Results Available	•Covid-19 Vaccine	•Diagnostic Test: Diagnostic of ECG	•Faculty of Tropical Medicine, BANGkok, Thailand
23	<a href="#">PROSPECTIVE OPEN LABEL CLINICAL TRIAL TO ADMINISTER A BOOSTER DOSE OF PFIZER/BIONTECH OR MODERNA COVID-19 VACCINE IN HIGH-RISK INDIVIDUALS</a>	Recruiting	No Results Available	•SARS CoV 2 Infection •COVID-19	•Biological: Pfizer/BioNTech (BNT162b2) •Biological: Moderna	•Brownsville Independent School District, Brownsville, Texas, United States •DHR Health Institute for Research and Development, Edinburg, Texas, United States •Edinburg CISD School Based Health Center, Edinburg, Texas, United States •Starr County Memorial Hospital, Rio Grande City, Texas, United States
24	<a href="#">Compare Immunological Efficacy of a Vaccine Regimen Combining Two Covid19 mRNA Vaccines (Pfizer-BioNTech and Moderna) With That of a Homologous Vaccination of Each Covid19 mRNA Vaccine</a>	Unknown status	No Results Available	•Adult Who Received a First Dose of an mRNA Vaccine (Pfizer-BioNTech or Moderna) and Need to Receive a Second Dose	•Biological: Pfizer •Biological: Moderna	•CIC 1417 Cochin-Pasteur, Paris, France
25	<a href="#">Phase 2a Trial to Evaluate Safety and Immunogenicity of COVID-19 Vaccine Strategies in HIV-infected/Uninfected Adults.</a>	Recruiting	No Results Available	•COVID-19	•Drug: Ad26.COV2.S (VAC31518, JNJ-78436735) Vaccine, SARS-CoV-2 rS (CovovaxTM), BNT162b2 (Pfizer)	•The Aurum Institute: Pretoria Clinical Research Centre, Pretoria, Gauteng, South Africa •The Aurum Institute: Tembisa Clinical Research Centre, Clinic 4, Tembisa, Gauteng, South Africa •The Aurum Institute: Tembisa Clinical Research Centre, Tembisa, Gauteng, South Africa •The Aurum Institute: Gavin J Churchyard Legacy Centre, Klerksdorp, North West Province, South Africa •The Aurum Institute: Rustenburg Clinical Research Centre, Rustenburg, North-West Province, South Africa
26	<a href="#">COVID-19: Safety and Immunogenicity of a Reduced Dose of the BioNTech/Pfizer BNT162b2 Vaccine</a>	Completed	No Results Available	•Covid19	•Diagnostic Test: immunogenicity after first and second dose	•Mensura EDPB, Antwerp, Belgium
27	<a href="#">Immune Response to the COVID-19 Vaccine</a>	Completed	No Results Available	•Covid19 •Cancer •Malignancy •Vaccine Response Impaired	•Biological: SARS-COV2 Pfizer Vaccine	•University of Arizona, Tucson, Arizona, United States

	Title	Status	Study Results	Conditions	Interventions	Locations
28	<a href="#">A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine Among Children in Brazil</a>	Completed	No Results Available	•COVID-19	•Biological: Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine  •Biological: CoronaVac COVID-19 vaccine	•Jardim Coopagro, Toledo, PR, Brazil  •Jardim Cosmos primary healthcare unit, Toledo, PR, Brazil  •Jardim Maracanã, Toledo, PR, Brazil  •Jardim Porto Alegre, Toledo, PR, Brazil  •Pediatric Emergency Service, Toledo, PR, Brazil
29	<a href="#">Determining Reactogenicity and Immunogenicity of Delayed COVID-19 Vaccine Schedule in Children</a>	Recruiting	No Results Available	•Vaccine Reaction  •COVID-19  •Children, Only	•Biological: BNT162b2 Pfizer-BioNTech/ Comirnaty	•KK Women's and Children's Hospital, Bukit Timah, Singapore
30	<a href="#">Lymph Node Aspiration to Decipher the Immune Response of Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine.</a>	Recruiting	No Results Available	•COVID-19	•Procedure: Lymph node aspiration / Blood sampling	•GH Broca-Cochin-Hôtel-Dieu CIC 1417 Cochin-Pasteur, Paris, France
31	<a href="#">Evaluation of COVID-19 Vaccines Given as a Booster in Healthy Adults in Indonesia (MIACoV Indonesia)</a>	Not yet recruiting	No Results Available	•COVID-19	•Biological: Pfizer-BioNTech Standard dose  •Biological: AstraZeneca Standard dose  •Biological: Pfizer-BioNTech Fractional dose  •Biological: AstraZeneca Fractional dose  •Biological: Moderna Standard dose  •Biological: Moderna Fractional dose	•Puskesmas Ciumbuleuit, Bandung, West Java, Indonesia  •Puskesmas Dago, Bandung, West Java, Indonesia  •Puskesmas Garuda, Bandung, West Java, Indonesia
32	<a href="#">An Observational Study of Moderna COVID-19 Bivalent Vaccines (Original and Omicron BA.4/BA.5) and 2023 Updated mRNA COVID-19 Vaccines (XBB.1.5)</a>	Active, not recruiting	No Results Available	•COVID-19	•Biological: Moderna COVID-19 Vaccine  •Biological: Moderna mRNA1273.222 Booster  •Biological: Pfizer COVID-19 Vaccine  •Biological: Moderna 2023 Updated COVID-19 vaccine (XBB.1.5)  •Biological: Pfizer 2023 Updated COVID-19 vaccine (XBB.1.5)	•Science37, Culver City, California, United States
33	<a href="#">Evaluation of Full Versus Fractional Doses of COVID-19 Vaccines Given as a Booster in Adults in Australia - Mongolia, Indonesia, Australia Coronavirus (MIACoV).</a>	Completed	No Results Available	•COVID-19	•Biological: Tozinameran - Standard dose  •Biological: Tozinameran - fractional dose  •Biological: Elasmomeran - standard dose  •Biological: Elasmomeran - fractional dose	•Royal Children's Hospital, Melbourne, Victoria, Australia
34	<a href="#">The Impact of Vaccination on Severity of Illness in COVID-19</a>	Completed	Has Results	•Covid19	•Biological: COVID-19 vaccine	•Beaumont Hospital - Royal Oak, Royal Oak, Michigan, United States
35	<a href="#">Effectiveness of BNT162b2 Formulations Using State Vaccine Registry and Insurance Claims Data</a>	Not yet recruiting	No Results Available	•SARS-CoV-2  •COVID-19 Vaccines	•Biological: Vaccination	•Pfizer Global Headquarters, New York, New York, United States
36	<a href="#">Immunogenicity of COVID-19 Vaccines in Tuberculosis Patients</a>	Enrolling by invitation	No Results Available	•Covid-19 Pandemics  •Tuberculosis	•Biological: Pfizer-BioNTech COVID-19 vaccine  •Biological: AstraZeneca vaccine  •Biological: Janssen Ad26.COV2.S COVID-19 vaccine	•Shoklo Malaria Research Unit (SMRU), Mae Ramat, Tak, Thailand
37	<a href="#">Safety and Immunogenicity of the RNA MCTI CIMATEC HDT Vaccine</a>	Not yet recruiting	No Results Available	•COVID-19  •COVID-19 Vaccine	•Biological: RNA MCTI CIMATEC HDT 5µg  •Biological: RNA MCTI CIMATEC HDT 10µg  •Biological: Covishield® - AstraZeneca  •Biological: Comirnaty® - Pfizer	



	Title	Status	Study Results	Conditions	Interventions	Locations
38	<a href="#">An Observer-blind, Cohort Randomized, Exploratory Phase 3 Study to Evaluate the Safety and Immunogenicity of Recombinant Covid-19 Vaccine, mRNA Covid-19 Vaccine and Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine as 4th Dose in Individuals Primed/ Boosted With Various Regimens</a>	Not yet recruiting	No Results Available	•COVID-19	•Biological: AstraZeneca/Fiocruz •Biological: Pfizer/Wyeth •Biological: Clover SCB-2019	•Centro de Estudos e Pesquisa em Moléstias Infecciosas (CEPCLIN), Natal, Rio Grande Do Norte, Brazil  •Crie Unifesp, São Paulo, SP, Brazil  •Hospital Gloria D'or, Rio De Janeiro, Brazil
39	<a href="#">Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase 4 Dose-optimizing Trial</a>	Recruiting	No Results Available	•COVID-19	•Biological: Sinovac •Biological: AZD1222 •Biological: BNT162b2	•FIOCRUZ, Campo Grande, MS Do Sul, Brazil  •Aga Khan University Clinical Trials Unit, Karachi, Sindh, Pakistan
40	<a href="#">COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations</a>	Completed	Has Results	•SARS-CoV Infection •COVID-19 •Allergic Reaction •Mast Cell Disorder	•Biological: Moderna COVID-19 Vaccine •Biological: Pfizer-BioNTech COVID-19 Vaccine •Biological: Placebo	•University of Arizona Health Sciences, College of Medicine Tucson, Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Tucson, Arizona, United States  •Arkansas Children's, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States  •University of California, Los Angeles Medical Center, Los Angeles, California, United States  •Stanford Medicine, Sean N. Parker Center for Allergy & Asthma Research, Stanford, California, United States  •National Jewish Health, Denver, Colorado, United States  •University Health, University of Miami Health System, Miami, Florida, United States  •University of South Florida Asthma Allergy and Immunology Clinical Research Unit, Tampa, Florida, United States  •Emory University School of Medicine, Emory Healthcare: Emory Clinic Allergy and Immunology, Atlanta, Georgia, United States  •Sinus and Allergy Center of Northwestern University, Chicago, Illinois, United States  •NorthShore University HealthSystem, Dermatology Clinical Trials Unit, Skokie, Illinois, United States  •and 19 more
41	<a href="#">Immunogenicity of Heterologous Versus Homologous Prime Boost Schedule With mRNA and Inactivated COVID-19 Vaccines</a>	Completed	No Results Available	•COVID-19	•Biological: CoronaVac/CoronaVac •Biological: CoronaVac/BNT162b2	•Leoni factory (Governorate of Bizerte), Bizerte, Mateur, Tunisia  •Géant supermarket (Governorate of Ariana), Ariana, Mnhla, Tunisia  •Vaccination center of Ariana, Ariana, Tunisia  •STEG head office (Governorate of Tunis), Tunis, Tunisia  •Institut Pasteur de Tunis, Tunis, Tunisia
42	<a href="#">The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose</a>	Completed	Has Results	•Systemic Allergic Reaction	•Biological: Pfizer-BioNTech COVID-19 Vaccine (Comirnaty) •Other: Placebo •Biological: Pfizer-BioNTech COVID-19 Vaccine, Bivalent	•National Institutes of Health Clinical Center, Bethesda, Maryland, United States
43	<a href="#">Assessment of Immunogenicity, Safety and Reactogenicity of a Booster Dose of Various COVID-19 Vaccine Platforms in Individuals Primed With Several Regimes.</a>	Active, not recruiting	No Results Available	•COVID-19	•Biological: SCB-2019/Clover •Biological: AstraZeneca/Fiocruz •Biological: Pfizer/Wyeth	•Centro de Estudos e Pesquisas em Moléstias Infecciosas - CEPCLIN, Natal, Rio Grande Do Norte, Brazil  •Centro de Referência para Imunobiológicos Especiais - CRIE - UNIFESP, São Paulo, Brazil
44	<a href="#">COVID-19 Breakthrough Infection in Fully Vaccinated People and in People Who Received a Booster Dose</a>	Completed	No Results Available	•COVID-19 Pneumonia •COVID-19	•Biological: Pfizer COVID-19 mRNA vaccine •Biological: Moderna COVID-19 mRNA vaccine	•Methodist Dallas Medical Center, Dallas, Texas, United States

	Title	Status	Study Results	Conditions	Interventions	Locations
45	<a href="#">A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.</a>	Not yet recruiting	No Results Available	<ul style="list-style-type: none"><li>•Influenza</li><li>•COVID-19</li></ul>	<ul style="list-style-type: none"><li>•Biological: Influenza and COVID-19 Combination A</li><li>•Biological: Licensed influenza vaccine</li><li>•Biological: COVID-19 Vaccine</li><li>•Biological: Influenza and COVID-19 Combination B</li><li>•Biological: Placebo</li></ul>	<ul style="list-style-type: none"><li>•North Alabama Research Center, Athens, Alabama, United States</li><li>•Accel Research Sites Network - Birmingham Clinical Research Unit, Birmingham, Alabama, United States</li><li>•Medical Affiliated Research Center, Huntsville, Alabama, United States</li><li>•Alliance for Multispecialty Research, LLC, Mobile, Alabama, United States</li><li>•HOPE Research Institute, Phoenix, Arizona, United States</li><li>•The Pain Center of Arizona, Phoenix, Arizona, United States</li><li>•Foothills Research Center/ CCT Research, Phoenix, Arizona, United States</li><li>•Scottsdale Clinical Trials, Scottsdale, Arizona, United States</li><li>•Alliance for Multispecialty Research, LLC, Tempe, Arizona, United States</li><li>•Baptist Health Center for Clinical Research, Little Rock, Arkansas, United States</li><li>•and 109 more</li></ul>
46	<a href="#">COVID-19 Fourth Dose Study in Australia</a>	Withdrawn	No Results Available	<ul style="list-style-type: none"><li>•COVID-19</li></ul>	<ul style="list-style-type: none"><li>•Biological: Tozinameran</li><li>•Biological: Elasomeran</li><li>•Biological: Bivalent Pfizer-BioNTech</li><li>•Biological: Bivalent Moderna</li></ul>	<ul style="list-style-type: none"><li>•Royal Children's Hospital, Murdoch Children's Research Institute, Melbourne, Victoria, Australia</li></ul>
47	<a href="#">Efficacy, Immunogenicity and Safety of Inactivated Vaccine (Coronavac) Against SARS-COV2 in Children and Adolescents</a>	Recruiting	No Results Available	<ul style="list-style-type: none"><li>•COVID-19</li></ul>	<ul style="list-style-type: none"><li>•Biological: Inactivated Coronavac/Butantan vaccine</li><li>•Biological: BNT162b2 (Pfizer)</li></ul>	<ul style="list-style-type: none"><li>•Valéria Valim, Vitória, Espírito Santo, Brazil</li></ul>
48	<a href="#">Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial</a>	Recruiting	No Results Available	<ul style="list-style-type: none"><li>•HIV</li><li>•Organ Transplantation</li><li>•Lymphoma, Non-Hodgkin</li><li>•Chronic Lymphocytic Leukemia</li><li>•Multiple Myeloma</li><li>•COVID-19 Vaccines</li></ul>	<ul style="list-style-type: none"><li>•Biological: Pfizer Bivalent COVID-19 Vaccine</li><li>•Biological: Moderna Bivalent mRNA vaccine</li></ul>	<ul style="list-style-type: none"><li>•Alfred Health, Melbourne, Victoria, Australia</li></ul>
49	<a href="#">Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Healthy Adults Volunteers Fully Vaccinated Followed by an Extension Period to Study a Fourth Dose Administration.</a>	Active, not recruiting	No Results Available	<ul style="list-style-type: none"><li>•COVID-19</li><li>•SARS-CoV-2 Acute Respiratory Disease</li></ul>	<ul style="list-style-type: none"><li>•Biological: COVID-19 Vaccine HIPRA</li><li>•Biological: Cominarty (Pfizer-BioNtech)</li></ul>	<ul style="list-style-type: none"><li>•Hospital Germans Trias I Pujol, Badalona, Barcelona, Spain</li><li>•Hospital Principe de Asturias, Meco, Madrid, Spain</li><li>•Hospital de Cruces, Barakaldo, Vizcaya, Spain</li><li>•Hospital Vall Hebron, Barcelona, Spain</li><li>•Hospital Clinic de Barcelona, Barcelona, Spain</li><li>•Hospital Universitari Dr. Josep Trueta, Girona, Spain</li><li>•Hospital Gregorio Marañón, Madrid, Spain</li><li>•Hospital Universitario La Paz, Madrid, Spain</li><li>•Hospital Regional Universitario de Málaga, Málaga, Spain</li><li>•Hospital Clínico de Valencia, Valencia, Spain</li></ul>
50	<a href="#">IH Convidecia as Second Booster Dose Against Breakthrough Infections</a>	Completed	No Results Available	<ul style="list-style-type: none"><li>•COVID-19</li></ul>	<ul style="list-style-type: none"><li>•Biological: Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)</li><li>•Biological: mRNA vaccine BNT162b2 (Pfizer)</li></ul>	<ul style="list-style-type: none"><li>•Hospital Ampang, Ampang, Selangor Darul Ehsan, Malaysia</li></ul>

	Title	Status	Study Results	Conditions	Interventions	Locations
51	<a href="#">A Study to Understand is the COVID-19 Vaccine BNT162b2 is Safe in Indonesia People</a>	Completed	No Results Available	•COVID-19	•Biological: BNT162b2	•Pfizer, Jakarta, Indonesia
52	<a href="#">Assessing the Immunogenicity and Safety of a HIPRA's Candidate Booster Vaccination in Adults Fully Vaccinated With Adenovirus Vaccine Against COVID-19.</a>	Completed	No Results Available	•COVID-19 •SARS-CoV-2 Acute Respiratory Disease	•Biological: COVID-19 Vaccine HIPRA 40 ug/dose  •Biological: Comirnaty (Pfizer-BioNtech) 30 ug/dose concentrate for dispersion for injection	•Hospital HM Modelo, Coruña, Spain •Hospital Gregorio Marañón, Madrid, Spain •Hospital HM Sanchinarro, Madrid, Spain •Hospital HM Puerta del Sur, Móstoles, Spain  •Complejo Hospitalario Universitario de Santiago, Santiago De Compostela, Spain  •Hospital HM Rosaleda, Santiago De Compostela, Spain  •Complejo Hospitalario Universitario de Vigo, Vigo, Spain
53	<a href="#">Immunogenicity and Safety of ChulaCov19 BNA159 and ChulaCov19 BNA159.2 Vaccines as a Booster Dose in Adults</a>	Recruiting	No Results Available	•COVID-19, SARS CoV 2 Infection	•Biological: ChulaCov19 BNA159 vaccine (50 mcg)  •Biological: Pfizer/BNT vaccine (30 mcg)  •Biological: COMVIGEN (ChulaCov19 BNA159.2) vaccine (50 mcg)	•Paratus research Canberra Clinic, Bruce, Australian Capital Territory, Australia  •Paratus Clinical Research Western Sydney, Blacktown, New South Wales, Australia  •Paratus Clinical Research Central Coast, Kanwal, New South Wales, Australia  •The Children's Hospital at Westmead Sydney, Westmead, New South Wales, Australia  •Paratus Clinical Research- Brisbane Clinic, Albion, Queensland, Australia
54	<a href="#">COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States</a>	Completed	No Results Available	•Immunocompromised •Immunosuppressed  •Covid-19 •SARS-COV-2 •SARS-COV-2 Infection •Breakthrough Infection	•Biological: BNT162b2 (Tozinameran)	•Pfizer Inc., New York, New York, United States
55	<a href="#">COVID-19 Vaccine Induced Immunity</a>	Unknown status	No Results Available	•Covid19	•Drug: covid19 vaccine	
56	<a href="#">SARS-CoV-2 Antibody Response in Children Aged 5-11 Years Following Vaccination Against COVID-19</a>	Unknown status	No Results Available	•COVID-19 Vaccine		•Schneider Children's Medical Center, Petach Tikva, Israel
57	<a href="#">Comparative Study of Patterns of Immune Response to COVID 19 Vaccination</a>	Recruiting	No Results Available	•Immune Response to Covid 19 Vaccination	•Biological: Covid vaccines (Moderna - Pfizer- Astra Zeneca- Johnson and Johnson - Sinopahrm)	•National Research Center, Cairo, Dokki, Egypt
58	<a href="#">Comparative Evaluation of Covid-19 Vaccines Response</a>	Unknown status	No Results Available	•COVID-19 Vaccines	•Biological: Covid-19 Inactive Vaccine, recombinant human adenovirus serotype number 26, mRNA VAccine	•Karamanoglu Mehmetbey University, Karaman, Turkey •Selcuk University, Konya, Turkey  •Tekirdag Nam#k Kemal University, Faculty of Medicine, Tekirda#, Turkey  •Karadeniz Technic University, Faculty of Medicine, Trabzon, Turkey
59	<a href="#">FDG (Fluorodeoxyglucose) Findings After COVID-19 Vaccination</a>	Completed	No Results Available	•Vaccine Reaction •Oncology	•Diagnostic Test: F-18 FDG PET/CT imaging  •Biological: Pfizer/biontech mRNA vaccine	•Kocaeli University School of Medicine Dep. of Nuclear Medicine, Kocaeli, Turkey
60	<a href="#">BNT162b2 Messenger Ribonucleic Acid (mRNA) Covid-19 Vaccine in Cancer Patients on Active Treatment</a>	Unknown status	No Results Available	•Neoplasms •Cancer, Treatment-Related	•Biological: BNT162b2 mRNA Covid-19 Vaccine	•E.O. Ospedali Galliera, Genova, Italy

	Title	Status	Study Results	Conditions	Interventions	Locations
61	<a href="#">A Study to Learn About Bivalent COVID-19 RNA Vaccine Candidate(s) in Healthy Infants and Children</a>	Not yet recruiting	No Results Available	•COVID-19	•Biological: Bivalent BNT162b2 (original/ Omicron BA.4/BA.5) 3 microgram dose  •Biological: Bivalent BNT162b2 (original/ Omicron BA.4/BA.5) 6 microgram dose  •Biological: Bivalent BNT162b2 (original/ Omicron BA.4/BA.5) 10 microgram dose  •Biological: Bivalent BNT162b2 (original/ Omicron BA.4/BA.5) 1 microgram dose	
62	<a href="#">A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza.</a>	Not yet recruiting	No Results Available	•COVID-19  •Coronavirus Disease 2019  •Influenza	•Biological: COVID-19 Vaccine	
63	<a href="#">Vaccination for Recovered Inpatients With COVID-19 (VATICO)</a>	Completed	No Results Available	•Covid19	•Biological: Moderna mRNA-1273 COVID-19 vaccine  •Biological: Pfizer BNT162b2 COVID-19 vaccine	•Cedars-Sinai Medical Center (Site 208-002), 8700 Beverly Blvd, Los Angeles, California, United States  •San Francisco VAMC (Site 074-002), 4150 Clement Street, San Francisco, California, United States  •Stanford University Hospitals & Clinics (Site 203-003), Stanford University, School of Medicine, 300 Pasteur Dr., Grant Bldg, Room S011, Stanford, California, United States  •Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (Site 066-002), 1124 W. Carson St., CDCRC, Torrance, California, United States  •Public Health Institute at Denver Health (Site 017-004), 660 Bannock Street, Denver, Colorado, United States  •Washington DC VA Medical Center (Site 009-004), 50 Irving Street, NW., Washington, District of Columbia, United States  •Hillsborough County Health Department, University of South Florida (Site 032-001), 1105 E. Kennedy Blvd., Tampa, Florida, United States  •Minneapolis VA Medical Center (Site 105-001), 1 Veterans Drive, Minneapolis, Minnesota, United States  •Duke University Hospital (Site 301-006), 2301 Erwin Road, Durham, North Carolina, United States  •Wake Forest Baptist Health (Site 210-001), Medical Center Boulevard, Winston-Salem, North Carolina, United States  •and 20 more
64	<a href="#">Intradermal Administration of a COVID-19 mRNA Vaccine in Elderly</a>	Recruiting	No Results Available	•Vaccination; Infection  •COVID-19	•Biological: Comirnaty	•Radboudumc, Nijmegen, Netherlands
65	<a href="#">Assessing Immune Response of Different COVID-19 Vaccines in Older Adults</a>	Completed	No Results Available	•Vaccination Reaction  •COVID-19  •Vaccination; Infection	•Biological: Comirnaty(BTN162b2)  •Biological: Spikevax (mRNA-1273)	•University Hospital Cologne, Cologne, Germany  •University Hospital Frankfurt, Frankfurt, Germany  •Hannover Medical School Hospital, Hannover, Germany  •Cork University Hospital, Cork, Ireland  •Royal College of Surgeons in Ireland, Dublin, Ireland  •St. Vincent's University Hospital, Dublin, Ireland  •Mater Misericordiae University Hospital, Dublin, Ireland  •St. James's Hospital, Dublin, Ireland  •Inlita JSC, Vilnius, Lithuania  •Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania  •and 6 more



	Title	Status	Study Results	Conditions	Interventions	Locations
66	<a href="#">Booster Dose of COVID-19 Vaccine for Kidney Transplant Recipients Without Adequate Humoral Response</a>	Unknown status	No Results Available	•COVID-19 Acute Respiratory Distress Syndrome •Immunosuppression	•Biological: The Pfizer mRNA-based BNT162b2 vaccine	
67	<a href="#">Adverse Reactions Following COVID-19 Vaccination Among Ecuadorian Healthcare Workers</a>	Completed	No Results Available	•Adverse Drug Event	•Biological: Pfizer-BioNTech COVID-19 vaccine	•Universidad Espiritu Santo, Samborondon, Ecuador
68	<a href="#">Semen Analysis Parameters Following Pfizer's COVID-19 Vaccine</a>	Unknown status	No Results Available	•Covid19 •Fertility Issues	•Other: Sperm collection	•Sheba medical center, Ramat Gan, Israel
69	<a href="#">CATCH-UP Vaccines: Extension of Community - Engaged Approaches to Testing in Community and Healthcare Settings for Underserved Populations (COVID-19)</a>	Recruiting	No Results Available	•COVID-19 •Vaccine Refusal	•Behavioral: Text Message •Behavioral: Motivational Interviewing •Behavioral: Electronic Educational Message with Tailored Questions/Prompts	•Oklahoma Clinical and Translational Science Institute, Oklahoma City, Oklahoma, United States
70	<a href="#">Safety and Immunogenicity of Recombinant Protein RBD Fusion Dimer Vaccine Against the Virus That Cause COVID-19, Known as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2)</a>	Active, not recruiting	No Results Available	•COVID-19 •SARS-CoV-2 Acute Respiratory Disease	•Biological: COVID-19 Vaccine HIPRA •Biological: Cominarty (Pfizer-BioNtech)	•National Institute of Hygiene and Epidemiology, Hanoi, Vietnam
71	<a href="#">Booster Study of COVID-19 Protein Subunit Recombinant Vaccine</a>	Recruiting	No Results Available	•COVID-19	•Biological: SARS-CoV-2 subunit protein recombinant vaccine •Biological: Active Comparator	•Faculty of Medicine Universitas Udayana, Denpasar, Bali, Indonesia •Faculty of Medicine Universitas Padjadjaran, Bandung, West Java, Indonesia
72	<a href="#">Hacettepe University COVID-19 Vaccinated's Health Cohort- Students of Health Sciences</a>	Active, not recruiting	No Results Available	•COVID-19 Pandemic •SARS-CoV2 Infection •Immunization; Infection •Health	•Other: Observational, prospective, follow-up of the recipients of CoronaVac (inactivated), Pfizer-Biontech (mRNA) vaccines	•Hacettepe University, S#hhiye Campus, Ankara, Turkey
73	<a href="#">COVID-19 Vaccination of Immunodeficient Persons (COVAXID)</a>	Active, not recruiting	No Results Available	•Covid19	•Biological: Comirnaty (COVID-19, mRNA vaccine)	•Karolinska University Hospital, Stockholm, Huddinge, Sweden
74	<a href="#">Reactogenicity, Immunogenicity and Inflammatory Response by New COVID-19 Vaccine Platforms</a>	Recruiting	No Results Available	•COVID-19 Vaccination •Inflammation •Vaccine Immune Response •Vaccine Adverse Reaction	•Biological: either BNT162b2 or ChAdOx1 vaccine	•Ajou University School of Medicine, Suwon, Gyeonggi-do, Korea, Republic of •Kangnam Sacred Heart Hospital, Seoul, Korea, Republic of •Korea University Guro Hospital, Seoul, Korea, Republic of
75	<a href="#">Evaluation of the Post-vaccination Immune Response to COVID-19 in the New Caledonian Population</a>	Completed	No Results Available	•SARS-CoV-2 Acute Respiratory Disease	•Other: Blood sample collection •Other: Questionnaires	•Centre Hospitalier Territorial de Nouvelle-Calédonie, Dumbéa Sur Mer, New Caledonia •Centre hospitalier spécialisé de Nouvelle-Calédonie, Nouméa, New Caledonia •Vaccination centers, Province Sud, New Caledonia
76	<a href="#">A Trial Among HealthCare Workers (HCW) Vaccinated With Janssen Vaccine: the SWITCH Trial</a>	Unknown status	No Results Available	•Covid19	•Biological: Vaccination once with Janssen vaccine (only priming) •Biological: Vaccination with Janssen vaccine followed with Janssen vaccine (homologous boosting). •Biological: Vaccination with Janssen vaccine followed with Moderna vaccine (heterologous boosting). •Biological: Vaccination with Janssen vaccine followed with Pfizer vaccine (heterologous boosting).	•AmsterdamUMC, Amsterdam, Netherlands •UMCG, Groningen, Netherlands •LUMC, Leiden, Netherlands •Erasmus MC, Rotterdam, Netherlands

	Title	Status	Study Results	Conditions	Interventions	Locations
77	<a href="#">A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children</a>	Completed	No Results Available	•SARS-CoV-2 Infection, COVID-19	•Biological: Biological/Vaccine: BNT162b2 10mcg  •Biological: BNT162b2 20mcg  •Biological: BNT162b2 30mcg  •Other: Placebo  •Biological: Biological/Vaccine: BNT162b2 3mcg	•University of Alabama at Birmingham - School of Medicine, Birmingham, Alabama, United States  •Phoenix Children's Hospital, Phoenix, Arizona, United States  •Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States  •SCPMG/Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States  •Matrix Clinical Research, Los Angeles, California, United States  •Madera Family Medical Group, Madera, California, United States  •Kaiser Permanente Oakland, Oakland, California, United States  •Clinical & Translational Research Unit (CTRU) & Spectrum BioBank, Stanford University, Palo Alto, California, United States  •Lucile Packard Children's Hospital Stanford, Palo Alto, California, United States  •Center for Clinical Trials, LLC, Paramount, California, United States  •and 136 more
78	<a href="#">Safety and Efficacy of COVID-19 Prime-boost Vaccine in Bahrain</a>	Completed	No Results Available	•SARS-CoV 2 Infection  •Covid19	•Biological: BBIBP-CorV  •Biological: BNT162b2	•Royal College of Surgeons in Ireland - Bahrain, Manama, Bahrain
79	<a href="#">A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children</a>	Recruiting	No Results Available	•SARS-CoV-2 Virus  •Severe Acute Respiratory Syndrome Coronavirus 2  •COVID-19	•Biological: Bivalent BNT162b2 (original/ Omicron BA.4/BA.5) 3 microgram dose  •Biological: Bivalent BNT162b2 (original/ Omicron BA.4/BA.5) 6 microgram dose  •Biological: Bivalent BNT162b2 (original/ Omicron BA.4/BA.5) 10 microgram dose  •Biological: Variant-adapted BNT162b2 (Omicron XBB.1.5) Substudy A Ph 2/3 Selected Dose  •Biological: Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose  •Biological: Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose  •Biological: Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose	•UAB Child Health Research Unit (CHRU), Birmingham, Alabama, United States  •UAB Child Health Research Unit (CHRU), Birmingham, Alabama, United States  •Phoenix Children's Hospital, Phoenix, Arizona, United States  •Northwest Arkansas Pediatric Clinic, Fayetteville, Arkansas, United States  •Paradigm Clinical Research Centers, Inc, La Mesa, California, United States  •Kaiser Permanente, Los Angeles, California, United States  •Clinical and Translational Research Unit (CTRU) & Spectrum Biobank, Palo Alto, California, United States  •Center for Clinical Trials, LLC, Paramount, California, United States  •Peninsula Research Associates, Rolling Hills Estates, California, United States  •Stanford University Medical Center, Stanford, California, United States  •and 81 more
80	<a href="#">Post COVID-19 Vaccination Analysis in Healthcare Worker Recipients</a>	Completed	No Results Available	•Covid19  •Vaccine Reaction	•Drug: COVID-19 vaccine	•Huntington Hospital, Pasadena, California, United States
81	<a href="#">Myocardial Injury After BNT162b2 mRNA COVID-19 Fourth Dose Vaccination Among Israeli Health Care Workers</a>	Completed	No Results Available	•Myocardial Injury  •Vaccine Adverse Reaction  •COVID-19	•Biological: BNT162b2	•Shaare zedek MC, Jerusalem, Israel

	Title	Status	Study Results	Conditions	Interventions	Locations
82	<a href="#">Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals</a>	Completed	No Results Available	<ul style="list-style-type: none"><li>•SARS-CoV-2 Infection</li><li>•COVID-19</li></ul>	<ul style="list-style-type: none"><li>•Biological: BNT162b1</li><li>•Biological: BNT162b2</li><li>•Other: Placebo</li><li>•Biological: BNT162b2SA</li></ul>	<ul style="list-style-type: none"><li>•North Alabama Research Center, LLC, Athens, Alabama, United States</li><li>•Birmingham Clinical Research Unit, Birmingham, Alabama, United States</li><li>•Medical Affiliated Research Center, Huntsville, Alabama, United States</li><li>•Optimal Research, LLC, Huntsville, Alabama, United States</li><li>•Alliance for Multispecialty Research, LLC, Mobile, Alabama, United States</li><li>•Chinle Comprehensive Health Care Facility, Chinle, Arizona, United States</li><li>•Johns Hopkins Center for American Indian Health, Chinle, Arizona, United States</li><li>•The Pain Center of Arizona, Phoenix, Arizona, United States</li><li>•HOPE Research Institute, Phoenix, Arizona, United States</li><li>•Alliance for Multispecialty Research, LLC, Tempe, Arizona, United States</li><li>•and 159 more</li></ul>
83	<a href="#">Effectiveness and Safety of COVID-19 Vaccine in Patients With IBD Treated With Immunomodulatory or Biological Drugs (ESCAPE-IBD)</a>	Unknown status	No Results Available	<ul style="list-style-type: none"><li>•Inflammatory Bowel Diseases</li></ul>	<ul style="list-style-type: none"><li>•Biological: Pfizer Comirnaty vaccine</li></ul>	
84	<a href="#">Study of GRT-R910 COVID-19 Boost Vaccine in Healthy Volunteers</a>	Completed	No Results Available	<ul style="list-style-type: none"><li>•COVID-19</li></ul>	<ul style="list-style-type: none"><li>•Biological: GRT-R910 10 mcg Dose (after AZ)</li><li>•Biological: GRT-R910 30 mcg Dose (after AZ)</li><li>•Biological: GRT-R910 10 mcg Dose (After Adenovirus based vaccine)</li><li>•Biological: GRT-R910 10 mcg Dose (after mRNA based vaccine)</li></ul>	<ul style="list-style-type: none"><li>•University Hospitals Birmingham NHS, Birmingham, United Kingdom</li><li>•University Hospital of Leicester NHS Trust, Leicester, United Kingdom</li><li>•Manchester University, Manchester, United Kingdom</li></ul>
85	<a href="#">SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine</a>	Completed	Has Results	<ul style="list-style-type: none"><li>•Covid19</li><li>•SARS-CoV2 Infection</li></ul>	<ul style="list-style-type: none"><li>•Biological: Study-provided Moderna mRNA-1273 COVID-19 vaccine</li><li>•Biological: Community-provided Moderna mRNA-1273 COVID-19 Vaccine</li><li>•Biological: Community-Provided Pfizer-BioNTech BNT162b2 COVID-19 Vaccine</li></ul>	<ul style="list-style-type: none"><li>•UCLA CARE Center CRS, Los Angeles, California, United States</li><li>•UCSD Antiviral Research Center CRS, San Diego, California, United States</li><li>•Rush University CRS (Site ID: 2702), Chicago, Illinois, United States</li><li>•Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS, Boston, Massachusetts, United States</li><li>•Chapel Hill CRS (Site ID: 3201), Chapel Hill, North Carolina, United States</li><li>•University of Washington AIDS CRS, Seattle, Washington, United States</li></ul>
86	<a href="#">Intradermal Tozinameran for Patients With Immune-mediated Dermatologic Diseases</a>	Active, not recruiting	No Results Available	<ul style="list-style-type: none"><li>•Bullous Dermatoses</li><li>•Psoriasis</li><li>•COVID-19 Vaccines</li></ul>	<ul style="list-style-type: none"><li>•Biological: tozinameran</li></ul>	<ul style="list-style-type: none"><li>•Dermatology outpatient clinic, Somdech Phra Debaratana Medical Center, Ramathibodi Hospital, Mahidol University, Ratchathewi, Bangkok, Thailand</li></ul>

	Title	Status	Study Results	Conditions	Interventions	Locations
87	<a href="#">A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals</a>	Active, not recruiting	No Results Available	<ul style="list-style-type: none"><li>•SARS-CoV-2 Infection</li><li>•COVID-19</li></ul>	<ul style="list-style-type: none"><li>•Biological: BNT162b5 Bivalent (WT/OMI BA.2)</li><li>•Biological: BNT162b2 Bivalent (WT/OMI BA.1)</li><li>•Biological: BNT162b2 Bivalent (WT/OMI BA.4/BA.5)</li><li>•Biological: BNT162b5 Bivalent (Original/ OMI BA.4/BA.5)</li><li>•Biological: BNT162b6 Bivalent (Original/ OMI BA.4/BA.5)</li><li>•Biological: BNT162b7 Bivalent (Original/ OMI BA.4/BA.5)</li><li>•Biological: BNT162b7 Monovalent (OMI BA.4/BA.5)</li></ul>	<ul style="list-style-type: none"><li>•Anaheim Clinical Trials, LLC, Anaheim, California, United States</li><li>•California Research Foundation, San Diego, California, United States</li><li>•Bayview Research Group, LLC, Valley Village, California, United States</li><li>•Diablo Clinical Research, Inc., Walnut Creek, California, United States</li><li>•Clinical Research Consulting, Milford, Connecticut, United States</li><li>•Research Centers of America ( Hollywood ), Hollywood, Florida, United States</li><li>•Clinical Neuroscience Solutions, Inc. dba CNS Healthcare, Jacksonville, Florida, United States</li><li>•Acevedo Clinical Research Associates, Miami, Florida, United States</li><li>•Clinical Research Atlanta, Stockbridge, Georgia, United States</li><li>•East-West Medical Research Institute, Honolulu, Hawaii, United States</li><li>•and 23 more</li></ul>
88	<a href="#">A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants</a>	Completed	Has Results	<ul style="list-style-type: none"><li>•SARS-CoV-2 Infection</li><li>•COVID-19</li></ul>	<ul style="list-style-type: none"><li>•Biological: BNT162b2</li><li>•Biological: BNT162b2.B.1.351</li></ul>	<ul style="list-style-type: none"><li>•Kaiser Permanente Oakland, Oakland, California, United States</li><li>•Clinical Research Consulting, Milford, Connecticut, United States</li><li>•Indago Research &amp; Health Center, Inc, Hialeah, Florida, United States</li><li>•Research Centers of America, Hollywood, Florida, United States</li><li>•Clinical Neuroscience Solutions, Orlando, Florida, United States</li><li>•Clinical Research Atlanta, Stockbridge, Georgia, United States</li><li>•East-West Medical Research Institute, Honolulu, Hawaii, United States</li><li>•Solaris Clinical Research, Meridian, Idaho, United States</li><li>•Kentucky Pediatric/Adult Research, Bardstown, Kentucky, United States</li><li>•Amici Clinical Research LLC, Raritan, New Jersey, United States</li><li>•and 7 more</li></ul>
89	<a href="#">Immunologic Responses to Single and Double Doses of COVID-19 Vaccines in Egyptians</a>	Unknown status	No Results Available	<ul style="list-style-type: none"><li>•COVID-19 Vaccines</li></ul>	<ul style="list-style-type: none"><li>•Biological: COVID-19 Vaccines</li></ul>	

	Title	Status	Study Results	Conditions	Interventions	Locations
90	<a href="#">A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza</a>	Active, not recruiting	No Results Available	<ul style="list-style-type: none"><li>•Influenza, Human</li><li>•COVID-19</li></ul>	<ul style="list-style-type: none"><li>•Biological: bivalent BNT162b2 (original/Omi BA.4/BA.5)</li><li>•Biological: qIRV (22/23)</li><li>•Biological: QIV</li><li>•Biological: bIRV</li><li>•Biological: tIRV</li></ul>	<ul style="list-style-type: none"><li>•North Alabama Research Center, Athens, Alabama, United States</li><li>•The Heart Center, Athens, Alabama, United States</li><li>•HOPE Research Institute, Phoenix, Arizona, United States</li><li>•The Pain Center of Arizona, Phoenix, Arizona, United States</li><li>•Orange County Heart Institute, Orange, California, United States</li><li>•California Research Foundation, San Diego, California, United States</li><li>•Orange County Research Center, Tustin, California, United States</li><li>•Proactive Clinical Research,LLC, Fort Lauderdale, Florida, United States</li><li>•Finlay Medical Research, Greenacres City, Florida, United States</li><li>•Indago Research &amp; Health Center, Inc, Hialeah, Florida, United States</li><li>•and 46 more</li></ul>
91	<a href="#">Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults</a>	Completed	Has Results	<ul style="list-style-type: none"><li>•SARS-CoV-2 Infection</li><li>•COVID-19</li></ul>	<ul style="list-style-type: none"><li>•Biological: BNT162b2</li><li>•Other: Placebo</li></ul>	<ul style="list-style-type: none"><li>•SOUSEIKAI Sumida Hospital, Sumida-ku, Tokyo, Japan</li><li>•SOUSEIKAI PS Clinic, Fukuoka, Japan</li></ul>
92	<a href="#">Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2</a>	Completed	Has Results	<ul style="list-style-type: none"><li>•Pneumococcal Disease</li><li>•COVID-19</li><li>•SARS-CoV-2 Infection</li></ul>	<ul style="list-style-type: none"><li>•Biological: 20-valent pneumococcal conjugate vaccine (20vPnC)</li><li>•Biological: BNT162b2</li><li>•Other: Saline</li></ul>	<ul style="list-style-type: none"><li>•Anaheim Clinical Trials, LLC, Anaheim, California, United States</li><li>•Diablo Clinical Research, Inc., Walnut Creek, California, United States</li><li>•Alliance for Multispecialty Research, LLC, Coral Gables, Florida, United States</li><li>•Indago Research &amp; Health Center, Inc, Hialeah, Florida, United States</li><li>•Research Centers of America ( Hollywood ), Hollywood, Florida, United States</li><li>•Acevedo Clinical Research Associates, Miami, Florida, United States</li><li>•Clinical Neuroscience Solutions, Orlando, Florida, United States</li><li>•Clinical Research Atlanta, Stockbridge, Georgia, United States</li><li>•East-West Medical Research Institute, Honolulu, Hawaii, United States</li><li>•Solaris Clinical Research, Meridian, Idaho, United States</li><li>•and 17 more</li></ul>



	Title	Status	Study Results	Conditions	Interventions	Locations
93	<a href="#">A Study to Learn About New COVID-19 RNA Vaccine Candidates for New Variants in Healthy Individuals</a>	Active, not recruiting	No Results Available	<ul style="list-style-type: none"> <li>•SARS-CoV-2 Infection</li> <li>•COVID-19</li> </ul>	<ul style="list-style-type: none"> <li>•Biological: BNT162b2 (Omi XBB.1.5)</li> </ul>	<ul style="list-style-type: none"> <li>•North Alabama Research Center, Athens, Alabama, United States</li> <li>•Medical Affiliated Research Center, Huntsville, Alabama, United States</li> <li>•Alliance for Multispecialty Research, LLC, Mobile, Alabama, United States</li> <li>•Epic Medical Research - Surprise, Surprise, Arizona, United States</li> <li>•Alliance for Multispecialty Research, LLC, Tempe, Arizona, United States</li> <li>•West Coast Research, Dublin, California, United States</li> <li>•California Research Foundation, San Diego, California, United States</li> <li>•Bayview Research Group, LLC, Valley Village, California, United States</li> <li>•Diablo Clinical Research, Inc., Walnut Creek, California, United States</li> <li>•Clinical Research Consulting, Milford, Connecticut, United States</li> <li>•and 30 more</li> </ul>
94	<a href="#">Immunogenicity and Safety of Comvigen (Bivalent) Vaccine</a>	Recruiting	No Results Available	<ul style="list-style-type: none"> <li>•Safety of a Single Dose of COMVIGEN Vaccine</li> <li>•Reactogenicity of a Single Dose of COMVIGEN Vaccine</li> <li>•Immunogenicity of a Single Dose of COMVIGEN Vaccine</li> <li>•Safety of a Single Dose of BIVALENT Pfizer/BNT Vaccine</li> <li>•Reactogenicity of a Single Dose of BIVALENT Pfizer/BNT Vaccine</li> <li>•Immunogenicity of a Single Dose of BIVALENT Pfizer/BNT Vaccine</li> </ul>	<ul style="list-style-type: none"> <li>•Biological: Comvigen (Bivalent, ChulaCov19 BNA159.2)</li> <li>•Biological: BIVALENT Pfizer/BNT vaccine</li> </ul>	<ul style="list-style-type: none"> <li>•Department of Pediatric, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand</li> <li>•HIV-NAT, Thai Red Cross - AIDS Research Centre, Bangkok, Thailand</li> </ul>
95	<a href="#">A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).</a>	Active, not recruiting	No Results Available	<ul style="list-style-type: none"> <li>•Healthy Participants</li> </ul>	<ul style="list-style-type: none"> <li>•Biological: Combination [RSVpreF +BNTb162b2]</li> <li>•Biological: Bivalent BNT162b2 (original/ Omi BA.4/BA.5)</li> <li>•Biological: RSVpreF</li> <li>•Biological: QIV</li> <li>•Biological: Normal Saline Placebo</li> </ul>	<ul style="list-style-type: none"> <li>•West Coast Research, Dublin, California, United States</li> <li>•Marvel Clinical Research, Huntington Beach, California, United States</li> <li>•Artemis Institute for Clinical Research, San Diego, California, United States</li> <li>•California Research Foundation, San Diego, California, United States</li> <li>•Orange County Research Center, Tustin, California, United States</li> <li>•Diablo Clinical Research, Inc., Walnut Creek, California, United States</li> <li>•Clinical Research Consulting, Milford, Connecticut, United States</li> <li>•Indago Research &amp; Health Center, Inc, Hialeah, Florida, United States</li> <li>•Wr-Msra.Llc, Lake City, Florida, United States</li> <li>•Optimal Research, Melbourne, Florida, United States</li> <li>•and 23 more</li> </ul>

	Title	Status	Study Results	Conditions	Interventions	Locations
96	<a href="#">Safety and Immunogenicity of LNP-nCOV saRNA-02 Vaccine Against SARS-CoV-2, the Causative Agent of COVID-19</a>	Recruiting	No Results Available	•COVID-19	•Drug: LNP-nCOV saRNA-02 Vaccine	•MRC/UVRI & LSHTM Uganda Research Unit, Entebbe, Uganda
97	<a href="#">Patient Experiences With the COVID-19 Vaccination After Breast Cancer Treatment</a>	Active, not recruiting	No Results Available	•Breast Cancer Related Lymphedema •Covid19	•Other: Survey	•Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
98	<a href="#">Effectiveness of mRNA Covid-19 Vaccines on Cancer Patients:Observational Study. (ANTICOV)</a>	Unknown status	No Results Available	•Cancer •Covid-19 •Vaccine Response	•Diagnostic Test: Serum collection, adverse events collection	•UO Oncologia, ASST di Cremona, Cremona, Lombardia, Italy
99	<a href="#">A Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine Booster in Healthy Adults</a>	Recruiting	No Results Available	•COVID-19	•Biological: Prime-2-CoV_Beta	•University Hospital Tübingen, Institute of Tropical Medicine, Tübingen, Baden-Württemberg, Germany •Bernhard-Nocht-Institut für Tropenmedizin, Hamburg, Germany
100	<a href="#">A Phase II/III Study to Evaluate the Immunogenicity and Safety and Efficacy of SWIM816 Vaccines for SARS-CoV-2</a>	Not yet recruiting	No Results Available	•Immunogenicity •Safety	•Biological: Phase II:SWIM816;SARS-Cov-2; •Biological: Phase II:SW-BIC-213;SARS-Cov-2; •Biological: PhaseIII:SWIM816;SARS-Cov-2; •Biological: PhaseIII:Pfizer(Pfizer Bivalent vaccine);SARS-Cov-2#	

80 additional studies not shown